249 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by New Covenant Trust Company N.A.

New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 249 shares of the biotechnology company’s stock, valued at approximately $32,000.

Several other institutional investors have also added to or reduced their stakes in the business. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $26,000. Mather Group LLC. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares during the period. Finally, CWM LLC raised its holdings in Sarepta Therapeutics by 178.7% in the 4th quarter. CWM LLC now owns 577 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 370 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Royal Bank of Canada upgraded shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $182.00 price target on the stock in a report on Monday. Mizuho increased their price target on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Evercore ISI boosted their price objective on shares of Sarepta Therapeutics from $139.00 to $185.00 and gave the stock an “in-line” rating in a research note on Monday, June 24th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $165.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $187.72.

Sarepta Therapeutics Stock Down 0.0 %

Shares of NASDAQ SRPT traded down $0.07 during mid-day trading on Friday, hitting $143.94. The company had a trading volume of 1,181,588 shares, compared to its average volume of 1,374,295. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25. The business’s 50-day simple moving average is $138.94 and its 200 day simple moving average is $130.56. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The company has a market capitalization of $13.61 billion, a PE ratio of 1,309.18 and a beta of 0.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same quarter in the previous year, the firm posted ($1.44) EPS. The firm’s revenue for the quarter was up 63.1% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current year.

Insider Activity

In other news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.